niacin and Blood Clot studies

Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.

Research Excerpts

Excerpt	Relevance	Reference
"In Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial, addition of extended-release niacin (ERN) to simvastatin in participants with established cardiovascular disease, low high-density lipoprotein cholesterol, and high triglycerides had no incremental benefit, despite increases in high-density lipoprotein cholesterol."	9.17	Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. ( Anderson, DC; Boden, WE; Chaitman, BR; Cruz-Flores, S; Goldstein, LB; Grant, S; Kostuk, WJ; Padley, RJ; Sila, CA; Teo, KK; Weintraub, WS, 2013)
"In Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial, addition of extended-release niacin (ERN) to simvastatin in participants with established cardiovascular disease, low high-density lipoprotein cholesterol, and high triglycerides had no incremental benefit, despite increases in high-density lipoprotein cholesterol."	5.17	Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. ( Anderson, DC; Boden, WE; Chaitman, BR; Cruz-Flores, S; Goldstein, LB; Grant, S; Kostuk, WJ; Padley, RJ; Sila, CA; Teo, KK; Weintraub, WS, 2013)
"Atherosclerosis is a chronic inflammatory disease affecting medium and large arteries resulting from a complex interaction between genetic and environmental risk factors that include dyslipidemia, hypertension, diabetes mellitus, and smoking."	2.47	Progress in HDL-based therapies for atherosclerosis. ( Chyu, KY; Peter, A; Shah, PK, 2011)

Research

Studies (31)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Cardiovascular Mortality

Timeframe	Studies, this research(%)	All Research%
pre-1990	21 (67.74)	18.7374
1990's	2 (6.45)	18.2507
2000's	3 (9.68)	29.6817
2010's	5 (16.13)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Teo, KK	1
Goldstein, LB	1
Chaitman, BR	1
Grant, S	1
Weintraub, WS	1
Anderson, DC	1
Sila, CA	1
Cruz-Flores, S	1
Padley, RJ	1
Kostuk, WJ	1
Boden, WE	1
Bach, P	1
Antonsson, T	1
Bylund, R	1
Björkman, JA	1
Österlund, K	1
Giordanetto, F	1
van Giezen, JJ	1
Andersen, SM	1
Zachrisson, H	1
Zetterberg, F	1
Hausenloy, DJ	1
Yellon, DM	1
Chyu, KY	1
Peter, A	1
Shah, PK	1
Shil, AB	1
Philipose, S	1
Konya, V	1
Lazarevic, M	1
Pasterk, LM	1
Marsche, G	1
Frank, S	1
Peskar, BA	1
Heinemann, A	1
Schuligoi, R	1
SCHIRMACHER, H	1
HEINRICH, P	1
TURPINI, R	1
CIPOLLI, PL	1
BARELLO, P	1
VINCKE, E	1
ESPOSITO, S	1
SOARDI, F	1
BLASCHKE, F	1
ORENGO, AM	1
MATTERA, RS	1
WAHAL, PK	1
MATHUR, KS	1
STOK, VN	1
NORMAND, J	1
DONNER, L	1
MENEGHINI, P	2
AVANZI, G	2
MORELLI, AC	1
PATEL, J	1
CORMIER, JM	1
SHERRY, S	1
PERRIN, A	1
FONTAINE, L	1
SAINT-PIERRE, A	1
SAILER, S	1
EBER, O	1
Ng, DS	1
Allman-Farinelli, MA	1
Dawson, B	1
Il'in, VN	1
Stepanov, NV	1
Ikhaev, ZA	1
Sharonin, GV	1
Bogdanets, LI	1
Sinzinger, H	1
Scanu, AM	1
Popov, AI	1
Kovaleva, LG	1
Sedova, GT	1
Krasiukova, LI	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
AIM HIGH: Niacin Plus Statin to Prevent Vascular Events[NCT00120289]	Phase 3	3,414 participants (Actual)	Interventional	2005-09-30	Terminated (stopped due to AIM-HIGH was stopped on the recommendation of the DSMB because of lack of efficacy of niacin in preventing primary outcome events.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination), for an average of 36 months follow-up, maximum 66 months.

Composite End Point of CHD Death, Nonfatal MI, Ischemic Stroke, Hospitalization for Non-ST Segment Elevation Acute Coronary Syndrome (ACS), or Symptom-driven Coronary or Cerebral Revascularization

Intervention	participants (Number)
ERN + Simvastatin	45
Placebo + Simvastatin	38

(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination) for an average of 36 months follow-up, maximum 66 months.

Composite Endpoint of CHD Death, Non-fatal MI, High-risk ACS or Ischemic Stroke

Intervention	participants (Number)
ERN + Simvastatin	282
Placebo + Simvastatin	274

(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination) for an average of 36 months follow-up, maximum 66 months

Composite Endpoint of CHD Death, Non-fatal MI, or Ischemic Stroke

Intervention	participants (Number)
ERN + Simvastatin	171
Placebo + Simvastatin	158